Alameda

This research aims to evaluate the effectiveness of a group-based Acceptance and Commitment Therapy ACT intervention in reducing psychological distress and enhancing quality of life in family caregivers of stroke survivors. It focuses on whether this group intervention can improve psychological flexibility and reduce experiential avoidance, which may influence caregiver outcomes. The study uses a quasi-experimental design comparing participants who receive the intervention with those who do not initially. Participants in the experimental group will attend a 5-week program consisting of weekly 1.5-hour group sessions based on the ACT model. The control group will not receive the intervention during this period but will complete the same assessments. After the experimental group finishes, the control group will then receive the same ACT intervention. Study measures will be collected before treatment, immediately after, and at a 2-month follow-up. During the study, participants will complete questionnaires assessing psychological flexibility, quality of life, experiential avoidance, and caregiver strain at three time points. The study monitors caregiver psychological distress and quality of life over time to determine if the ACT group intervention provides benefits. Participation involves regular group sessions and completing standardized assessments, with the entire study extending through initial treatment and follow-up periods.

Researchers are evaluating ivonescimab as a first-line treatment for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. This phase 3 study compares ivonescimab to pembrolizumab, focusing on overall survival and progression-free survival to understand which treatment may better support patients with this condition. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab through intravenous injection. The study is double-blinded and multiregional, involving continuous treatment and monitoring for up to approximately 36 months. Both groups receive their assigned treatment regularly during this period, with careful observation of treatment responses and side effects. During the trial, participants will undergo evaluations including scans to measure tumor size, laboratory tests, and assessments of adverse events. Researchers will track overall survival, progression-free survival, response rates, disease control, and duration of response. Safety monitoring will continue for up to 24 months after the last dose. The total study period extends until June 2029, allowing long-term data collection on treatment effects and safety.